Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
692 Circulating tumor DNA analysis of advanced hepatocellular cancer (HCC) patients treated with neoantigen targeted personalized cancer DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab)
Compose a Response to This Article
Other responses
No responses have been published for this article.